Silicone hydrogel versus hydrogel soft contact lenses for differences in patient-reported eye comfort and safety.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
19 09 2023
Historique:
pmc-release: 19 09 2024
medline: 21 9 2023
pubmed: 19 9 2023
entrez: 19 9 2023
Statut: epublish

Résumé

Ocular discomfort is the leading cause of permanent discontinuation of soft contact lens (SCL) wear. Silicone hydrogel and hydrogel materials are the two major categories of SCLs, with silicone hydrogel materials being newer and more breathable than hydrogel materials. Whether comfort is associated with SCL material is controversial despite numerous studies. Similarly, the difference between these materials in terms of safety outcomes (e.g. frequency of microbial keratitis) is unclear. To evaluate the comparative effectiveness and safety of silicone hydrogel compared with hydrogel SCLs on self-reported comfort, dry eye test results, and adverse events in SCL-wearing adults 18 years of age or older. The Cochrane Eyes and Vision Information Specialist searched the electronic databases for randomized controlled trials (RCTs). There were no restrictions on language or date of publication. We searched the Cochrane Central Register of Controlled Trials (CENTRAL, including the Cochrane Eyes and Vision Trials Register; 2022, Issue 6), MEDLINE Ovid, Embase.com, PubMed, LILACS (Latin American and Caribbean Health Science Information database), ClinicalTrials.gov, and World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We also searched the reference lists of identified studies, review articles, and guidelines for information about relevant studies that may not have been identified by our search strategy. Furthermore, we contacted investigators regarding ongoing trials. The most recent database search was conducted on 24 June 2022. Our search selection criteria included RCTs, quasi-RCTs, and cross-over RCTs. We applied standard Cochrane methodology. We included seven parallel-group RCTs conducted in the USA, the UK, Australia, Germany, India, and Turkey. A total of 1371 participants were randomized. The duration of SCL wear ranged from one to 52 weeks. Study characteristics and risk of bias The median number of participants per trial was 120 (interquartile range: 51 to 314), and the average age ranged from 20.7 to 33.0 years. Women represented the majority of participants (range 55% to 74.9%; 5 RCTs). Collectively, the included trials compared eight different silicone hydrogel SCLs with three different hydrogel SCLs. Five trials compared daily disposable SCLs, and two compared extended wear SCLs (worn for seven days and six nights). New SCL wearers were enrolled in three trials. Two trials included both new and established SCL wearers, and two trials did not report participants' history of SCL use. Five trials were sponsored by industry. We judged the overall risk of bias to be 'high' or 'some concerns' for the safety and efficacy outcomes. Findings One trial reported Ocular Surface Disease Index (OSDI) results, with the evidence being very uncertain about the effects of SCL material on OSDI scores (mean difference -1.20, 95% confidence interval [CI] -10.49 to 8.09; 1 RCT, 47 participants; very low certainty evidence). Three trials reported visual analog scale comfort score results, with no clear difference in comfort between materials, but the evidence was of very low certainty; trial results could not be combined because the three trials reported results at different time points. The evidence is very uncertain about the effect of SCL material on discontinuation of contact lens wear (risk ratio [RR] 0.64, 95% CI 0.11 to 3.74; 1 RCT, 248 participants). None of the included trials reported Contact Lens Dry Eye Questionnaire (CLDEQ-8) or Standard Patient Evaluation of Eye Dryness (SPEED) scores. There was no evidence of a clinically meaningful difference (> 0.5 unit) between daily disposable silicone hydrogel and hydrogel SCLs in corneal staining, conjunctival staining, or conjunctival redness (very low certainty evidence). Adverse events Very low certainty evidence from two trials comparing daily disposable SCLs suggested no evidence of a difference between lens materials in the risk of vision-threatening adverse events at one to four weeks (RR 0.68, 95% CI 0.08 to 5.51; 2 RCTs, 368 participants). Two trials comparing extended wear SCLs indicated that hydrogel SCLs may have a 2.03 times lower risk of adverse events at 52 weeks compared with silicone hydrogel SCLs (RR 2.03, 95% CI 1.38 to 2.99; 815 participants), but the certainty of evidence was very low. The overall evidence for a difference between all included silicone hydrogel and hydrogel SCLs was of very low certainty, with most trials at high overall risk of bias. The majority of studies did not assess comfort using a validated instrument. There was insufficient evidence to support recommending one SCL material over the other. For extended wear, hydrogel SCL may have a lower risk of adverse events at 52 weeks compared to silicon hydrogel. Future well-designed trials are needed to generate high certainty evidence to further clarify differences in SCL material comfort and safety.

Sections du résumé

BACKGROUND
Ocular discomfort is the leading cause of permanent discontinuation of soft contact lens (SCL) wear. Silicone hydrogel and hydrogel materials are the two major categories of SCLs, with silicone hydrogel materials being newer and more breathable than hydrogel materials. Whether comfort is associated with SCL material is controversial despite numerous studies. Similarly, the difference between these materials in terms of safety outcomes (e.g. frequency of microbial keratitis) is unclear.
OBJECTIVES
To evaluate the comparative effectiveness and safety of silicone hydrogel compared with hydrogel SCLs on self-reported comfort, dry eye test results, and adverse events in SCL-wearing adults 18 years of age or older.
SEARCH METHODS
The Cochrane Eyes and Vision Information Specialist searched the electronic databases for randomized controlled trials (RCTs). There were no restrictions on language or date of publication. We searched the Cochrane Central Register of Controlled Trials (CENTRAL, including the Cochrane Eyes and Vision Trials Register; 2022, Issue 6), MEDLINE Ovid, Embase.com, PubMed, LILACS (Latin American and Caribbean Health Science Information database), ClinicalTrials.gov, and World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We also searched the reference lists of identified studies, review articles, and guidelines for information about relevant studies that may not have been identified by our search strategy. Furthermore, we contacted investigators regarding ongoing trials. The most recent database search was conducted on 24 June 2022.
SELECTION CRITERIA
Our search selection criteria included RCTs, quasi-RCTs, and cross-over RCTs.
DATA COLLECTION AND ANALYSIS
We applied standard Cochrane methodology.
MAIN RESULTS
We included seven parallel-group RCTs conducted in the USA, the UK, Australia, Germany, India, and Turkey. A total of 1371 participants were randomized. The duration of SCL wear ranged from one to 52 weeks. Study characteristics and risk of bias The median number of participants per trial was 120 (interquartile range: 51 to 314), and the average age ranged from 20.7 to 33.0 years. Women represented the majority of participants (range 55% to 74.9%; 5 RCTs). Collectively, the included trials compared eight different silicone hydrogel SCLs with three different hydrogel SCLs. Five trials compared daily disposable SCLs, and two compared extended wear SCLs (worn for seven days and six nights). New SCL wearers were enrolled in three trials. Two trials included both new and established SCL wearers, and two trials did not report participants' history of SCL use. Five trials were sponsored by industry. We judged the overall risk of bias to be 'high' or 'some concerns' for the safety and efficacy outcomes. Findings One trial reported Ocular Surface Disease Index (OSDI) results, with the evidence being very uncertain about the effects of SCL material on OSDI scores (mean difference -1.20, 95% confidence interval [CI] -10.49 to 8.09; 1 RCT, 47 participants; very low certainty evidence). Three trials reported visual analog scale comfort score results, with no clear difference in comfort between materials, but the evidence was of very low certainty; trial results could not be combined because the three trials reported results at different time points. The evidence is very uncertain about the effect of SCL material on discontinuation of contact lens wear (risk ratio [RR] 0.64, 95% CI 0.11 to 3.74; 1 RCT, 248 participants). None of the included trials reported Contact Lens Dry Eye Questionnaire (CLDEQ-8) or Standard Patient Evaluation of Eye Dryness (SPEED) scores. There was no evidence of a clinically meaningful difference (> 0.5 unit) between daily disposable silicone hydrogel and hydrogel SCLs in corneal staining, conjunctival staining, or conjunctival redness (very low certainty evidence). Adverse events Very low certainty evidence from two trials comparing daily disposable SCLs suggested no evidence of a difference between lens materials in the risk of vision-threatening adverse events at one to four weeks (RR 0.68, 95% CI 0.08 to 5.51; 2 RCTs, 368 participants). Two trials comparing extended wear SCLs indicated that hydrogel SCLs may have a 2.03 times lower risk of adverse events at 52 weeks compared with silicone hydrogel SCLs (RR 2.03, 95% CI 1.38 to 2.99; 815 participants), but the certainty of evidence was very low.
AUTHORS' CONCLUSIONS
The overall evidence for a difference between all included silicone hydrogel and hydrogel SCLs was of very low certainty, with most trials at high overall risk of bias. The majority of studies did not assess comfort using a validated instrument. There was insufficient evidence to support recommending one SCL material over the other. For extended wear, hydrogel SCL may have a lower risk of adverse events at 52 weeks compared to silicon hydrogel. Future well-designed trials are needed to generate high certainty evidence to further clarify differences in SCL material comfort and safety.

Identifiants

pubmed: 37724689
doi: 10.1002/14651858.CD014791.pub2
pmc: PMC10507745
doi:

Substances chimiques

Silicones 0
Hydrogels 0

Types de publication

Systematic Review Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD014791

Subventions

Organisme : NEI NIH HHS
ID : UG1 EY020522
Pays : United States

Informations de copyright

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Références

CLAO J. 1995 Oct;21(4):221-32
pubmed: 8565190
Cornea. 2007 Feb;26(2):168-74
pubmed: 17251807
Eye Contact Lens. 2013 Jan;39(1):13-9
pubmed: 23271477
Optom Vis Sci. 2000 Jan;77(1):40-6
pubmed: 10654857
Cont Lens Anterior Eye. 2019 Jun;42(3):318-324
pubmed: 30538060
Optom Vis Sci. 1993 Mar;70(3):234-43
pubmed: 8483586
Eye Contact Lens. 2018 Nov;44 Suppl 2:S1-S10
pubmed: 29373389
Clin Optom (Auckl). 2020 Jun 25;12:85-94
pubmed: 32612404
Eye Contact Lens. 2003 Jan;29(1):50-4
pubmed: 12769158
Ophthalmology. 2002 Jun;109(6):1172-7
pubmed: 12045062
Eye Contact Lens. 2003 Jan;29(1):55-9
pubmed: 12769159
Cont Lens Anterior Eye. 2022 Aug;45(4):101498
pubmed: 34373201
Cornea. 2013 Sep;32(9):1204-10
pubmed: 23846405
Cont Lens Anterior Eye. 2000;23(2):53-60
pubmed: 16303433
J Biomed Opt. 2006 May-Jun;11(3):34028
pubmed: 16822077
Eye Contact Lens. 2013 Jan;39(1):93-9
pubmed: 23266586
Optom Vis Sci. 2001 Feb;78(2):95-9
pubmed: 11265932
Cont Lens Anterior Eye. 2021 Aug;44(4):101370
pubmed: 33071184
Clin Exp Optom. 2011 Jul;94(4):352-60
pubmed: 21323732
Eye Contact Lens. 2013 Jan;39(1):125-9
pubmed: 23266592
Eye Contact Lens. 2007 May;33(3):148-55
pubmed: 17502750
Eye Contact Lens. 2021 Dec 1;47(12):631-637
pubmed: 34797270
Cornea. 2002 Jul;21(5):469-75
pubmed: 12072721
Oftalmologia. 2006;50(2):126-8
pubmed: 16927771
Eye Contact Lens. 2018 May;44(3):190-199
pubmed: 27768615
Cochrane Database Syst Rev. 2023 Sep 19;9:CD014791
pubmed: 37724689
Cont Lens Anterior Eye. 2021 Apr;44(2):289-329
pubmed: 33775381
Clin Ophthalmol. 2021 Oct 29;15:4339-4345
pubmed: 34744430
Optom Vis Sci. 2013 Apr;90(4):344-50
pubmed: 23478632
Cornea. 2019 May;38(5):587-594
pubmed: 30933963
Cont Lens Anterior Eye. 2016 Jun;39(3):203-9
pubmed: 26639027
Invest Ophthalmol Vis Sci. 2015 Jan 08;56(1):654-63
pubmed: 25574042
J Am Optom Assoc. 1986 Jul;57(7):512-7
pubmed: 3489027
Cornea. 2008 Oct;27(9):976-9
pubmed: 18812757
Eye Contact Lens. 2013 Jan;39(1):115-24
pubmed: 23271473
Optom Vis Sci. 2018 Dec;95(12):1096-1104
pubmed: 30451806
Ophthalmic Physiol Opt. 2001 Jan;21(1):17-29
pubmed: 11220037
Cont Lens Anterior Eye. 2022 Apr;45(2):101426
pubmed: 33618977
Eye Contact Lens. 2017 Jan;43(1):32-39
pubmed: 28002225
Optom Vis Sci. 1997 Aug;74(8):624-31
pubmed: 9323733
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3307-3313
pubmed: 30025086
Clin Optom (Auckl). 2017 Feb 15;9:41-48
pubmed: 30214359
Cont Lens Anterior Eye. 2010 Aug;33(4):196-8
pubmed: 20056474
Eye Contact Lens. 2013 Jan;39(1):86-92
pubmed: 23274759
Cont Lens Anterior Eye. 2013 Feb;36(1):4-12
pubmed: 23116923
Cont Lens Anterior Eye. 2021 Apr;44(2):192-219
pubmed: 33775377
Invest Ophthalmol Vis Sci. 2016 Jan 1;57(1):47-55
pubmed: 26780309
Cont Lens Anterior Eye. 2022 Apr;45(2):101515
pubmed: 34583895
Cont Lens Anterior Eye. 2022 Oct;45(5):101596
pubmed: 35466057
Cornea. 2009 Aug;28(7):789-94
pubmed: 19574906
CLAO J. 1997 Jan;23(1):43-8
pubmed: 9001771
Optom Vis Sci. 2000 Oct;77(10):503-10
pubmed: 11100888
Cont Lens Anterior Eye. 2021 Aug;44(4):101387
pubmed: 33308907
Eye Contact Lens. 2018 Nov;44 Suppl 2:S233-S240
pubmed: 29077584
Biomaterials. 2001 Dec;22(24):3273-83
pubmed: 11700799
Cornea. 2003 Nov;22(8):740-5
pubmed: 14576525
Eye Contact Lens. 2005 Jan;31(1):2-8
pubmed: 15665665
Optom Vis Sci. 1990 Jun;67(6):391-9
pubmed: 2199882
Optom Vis Sci. 2001 Mar;78(3):147-51
pubmed: 11327675
J Clin Epidemiol. 2022 Oct;150:225-242
pubmed: 35934266
Optom Vis Sci. 2013 Jul;90(7):674-81
pubmed: 23792305
Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3325-9
pubmed: 16877398
Ophthalmology. 2016 May;123(5):1036-42
pubmed: 26875007
Eye Contact Lens. 2013 Jan;39(1):20-23
pubmed: 23266585
Cont Lens Anterior Eye. 2007 Mar;30(1):23-8
pubmed: 17178252
Arq Bras Oftalmol. 2008 Nov-Dec;71(6 Suppl):37-41
pubmed: 19274409
Int Contact Lens Clin. 1999 Nov;26(6):157-162
pubmed: 11384832
Ophthalmic Physiol Opt. 2013 Mar;33(2):94-103
pubmed: 23406489
Clin Exp Optom. 2007 Mar;90(2):124-31
pubmed: 17311574
Eye Contact Lens. 2013 Jan;39(1):79-85
pubmed: 23172318
Cesk Oftalmol. 1961 Jan;17:70-5
pubmed: 13784992
Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3043-50
pubmed: 17591871
Optom Vis Sci. 2007 Apr;84(4):247-56
pubmed: 17435508
Invest Ophthalmol Vis Sci. 2013 Oct 18;54(11):TFOS37-70
pubmed: 24058138
Optom Vis Sci. 2004 Dec;81(12):911-21
pubmed: 15592115
Eye Contact Lens. 2007 Nov;33(6 Pt 2):343-5; discussion 362-3
pubmed: 17975417
CLAO J. 1991 Apr;17(2):114-9
pubmed: 2049819
Eye Contact Lens. 2012 Jan;38(1):16-26
pubmed: 22146704
J Ophthalmic Vis Res. 2017 Apr-Jun;12(2):193-204
pubmed: 28540012
Optom Vis Sci. 2015 Jul;92(7):758-67
pubmed: 26101823
Ophthalmic Physiol Opt. 2002 Nov;22(6):516-27
pubmed: 12477016
Invest Ophthalmol Vis Sci. 1984 Oct;25(10):1161-7
pubmed: 6592160
Biomed Eng Online. 2018 Nov 1;17(1):164
pubmed: 30382929
Optom Vis Sci. 2020 Mar;97(3):178-185
pubmed: 32168240
Optom Vis Sci. 2009 Apr;86(4):340-9
pubmed: 19225433
Arch Ophthalmol. 2000 May;118(5):615-21
pubmed: 10815152
Optom Vis Sci. 2017 Apr;94(4):496-504
pubmed: 28009794
Cornea. 2003 Oct;22(7):640-50
pubmed: 14508260
Optom Vis Sci. 2012 Oct;89(10):1435-42
pubmed: 22960615
Clin Optom (Auckl). 2020 Jan 14;12:9-15
pubmed: 32021532
Ophthalmic Physiol Opt. 2001 Jan;21(1):30-5
pubmed: 11220038
Cont Lens Anterior Eye. 2022 Oct;45(5):101579
pubmed: 35246387
Optom Vis Sci. 2019 Apr;96(4):283-290
pubmed: 30907859
Optom Vis Sci. 2013 Sep;90(9):945-53
pubmed: 23892493
Eye Contact Lens. 2013 Jan;39(1):53-60
pubmed: 23271474
Cont Lens Anterior Eye. 2021 Apr;44(2):330-367
pubmed: 33775382
Eye Contact Lens. 2018 Sep;44 Suppl 1:S167-S172
pubmed: 28099285
Eye Contact Lens. 2003 Jan;29(1 Suppl):S131-4; discussion S143-4, S192-4
pubmed: 12772749
Optom Vis Sci. 2014 Jan;91(1):3-12
pubmed: 24240354
Eye Contact Lens. 2012 Sep;38(5):313-8
pubmed: 22890226
Syst Rev. 2013 Sep 23;2:81
pubmed: 24059250
Cont Lens Anterior Eye. 2022 Oct;45(5):101574
pubmed: 35101386
J Med Libr Assoc. 2006 Apr;94(2):130-6
pubmed: 16636704
Optom Vis Sci. 2012 Dec;89(12):1682-90
pubmed: 23190713
Cont Lens Anterior Eye. 2009 Dec;32(6):288-93
pubmed: 19592292
Eye Contact Lens. 2018 Sep;44 Suppl 1:S30-S37
pubmed: 27341089
N Engl J Med. 1989 Sep 21;321(12):779-83
pubmed: 2770809
Invest Ophthalmol Vis Sci. 2003 Jan;44(1):68-77
pubmed: 12506057
J Am Optom Assoc. 1987 Apr;58(4):296-301
pubmed: 3584792

Auteurs

Kristina Haworth (K)

Southern College of Optometry, Memphis, Tennessee, USA.

Darian Travis (D)

School of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Louis Leslie (L)

Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Daniel Fuller (D)

Cornea Contact Lens Service, The Eye Center, Southern College of Optometry, Memphis, TN, USA.

Andrew D Pucker (AD)

School of Optometry, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH